KLRK1 and acute myeloid leukemia: However, two preliminary studies and one completed clinical study have shown a lack of substantial clinical efficacy of NKG2D-CAR T cells in r/r AML, which was associated with poor in vivo persistence of CAR-T cells, possibly due to the fratricide effect of targeting MICA/MICB in CAR-T cells [38,39,40].